From The Editor

  1. A Maverick Gene Therapy Manufacturing Strategy 6/11/2021

    Sio Gene Therapies CEO Pavan Cheruvu explains the company’s rationale for migrating away from a hybrid in-house/CDMO manufacturing model to a fully insourced one. 

  2. GMP CAR T Manufacturing: The Poseida Approach 6/7/2021

    Promising clinical momentum and a recent IPO are fueling Poseida Therapeutics’ unique approach to manufacturing safe, accessible, and affordable allogeneic CAR T-cell therapies. CEO Eric Ostertag, M.D., Ph.D., shares the company’s differentiating factors.

  3. Semper Fi: What The Marines Taught A Biopharma CEO 6/3/2021

    Before earning his law degree and crafting a career as a biotech entrepreneur, Daniel O’Connor, J.D. was Marine Captain Daniel O’Connor. He earned that rank in Saudi Arabia, where he was deployed to serve Operation Desert Shield just days following Iraq's invasion of Kuwait. On a recent episode of the Business of Biotech podcast, he shared how being a Marine prepared him for leadership of a blossoming biopharma company.

  4. SOTIO’s Quest To Build A Global Biopharma 5/28/2021

    While many clinical-stage biopharmas consider the “end” an “exit,” PPF-backed SOTIO’s intention is to build an oncology-focused biopharma company that stands on its own broad and diverse pipeline. Its CEO sat down with the Business of Biotech podcast to share the company’s strategy.

  5. Manufacturing A mAb For Congenital Hyperinsulinism 5/28/2021

    Rezolute Inc. CEO & Founder Nevan Charles Elam, J.D. shares an update on the company’s effort to address congenital hyperinsulinism with the human monoclonal antibody RZ358, addressing pandemic-fueled CDMO capacity constraints and capitalizing on Rare Pediatric Disease Designation along the way. 

  6. Beating Herpes: Inside X-VAX’s Vaccine Candidate 5/18/2021

    An inside look at preclinical stage biotech, X-VAX, which is preparing to engage the FDA with data on an HSV vaccine candidate that could have therapeutic impact on a virus carried by the majority of the world’s population. 

  7. BeiGene, FDA, ACPHS Announce Pharmacovigilance Fellowship 5/18/2021

    BeiGeine, the FDA, and Albany College of Pharmacy and Health Sciences are setting a new standard for collaborative cultivation of next-gen life sciences talent by breaking down barriers between academia, industry, and the Agency. We go inside their innovative Fellowship model. 

  8. The Placental Stem Cell Advantage 5/11/2021

    As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research into practice. Could the production platform it’s building be the key to accessible, affordable allogeneic cell therapy?

  9. Decentralized Cell Therapy Production In Practice 4/21/2021

    Distributing the manufacture of autologous cell therapies to clinical and hospital settings to minimize time, cost, and logistics challenges is a popular conversation in biopharma circles. While many discuss it, Dr. Helen Sabzevari’s upstart biopharma Precigen is doing it.

  10. Inside San Jose’s Uncommon Biotech Accelerator 4/21/2021

    San Jose BioCube takes a unique approach to the incubator/accelerator model, capitalizing on big demand for the space that emerging-to-midsize biotechs need to grow their businesses. As a result, the accelerator is growing, too. Learn more about what to look for in accelerator space, whether or not you're in the Bay area.